Pediatrics · Year 3 · from Pediatrics

Case 2: Precocious Puberty

Patient Demographics

  • Age: 6-year-old female
  • Sex: Female

Chief Complaint

"My daughter is developing breasts and I'm worried it's too early."

History of Present Illness

A 6-year-old girl is brought in by her mother who noticed breast development starting approximately 6 months ago with progressive enlargement. The mother also reports she has grown 3 inches in the past year, which is faster than her older siblings grew at this age. There is no history of headaches, visual changes, seizures, or behavioral changes. The child has no exposure to hormonal creams, supplements, or medications. No pubic or axillary hair has been noted. There is no vaginal bleeding.

Growth Parameters

  • Height: 125 cm (97th percentile, +2.1 SD)
  • Weight: 26 kg (90th percentile)
  • BMI: 16.6 kg/m2 (75th percentile)
  • Growth velocity: 9 cm/year (accelerated)

Physical Examination

  • General: Well-appearing girl, appears older than stated age
  • HEENT: Normal, visual fields intact
  • Thyroid: Normal
  • Cardiovascular: Normal
  • Abdomen: Soft, non-tender
  • Breast: Tanner stage III bilateral breast development (elevated breast contour, no areolar separation)
  • Genitourinary: Tanner stage I pubic hair, normal external genitalia, no clitoromegaly, estrogenized vaginal mucosa
  • Skin: No cafe-au-lait spots
  • Neurologic: Normal

Workup

  • Bone age: 8.5 years (advanced 2.5 years)
  • LH (basal): 1.8 mIU/mL (pubertal range)
  • FSH: 4.2 mIU/mL
  • Estradiol: 28 pg/mL (elevated)
  • GnRH stimulation test: LH rises to 12 mIU/mL (pubertal response)
  • TSH: Normal
  • Pelvic ultrasound: Enlarged uterus (4.2 cm length) with endometrial stripe, bilateral enlarged ovaries with multiple follicles
  • Brain MRI: Normal, no hypothalamic-pituitary lesions

Diagnosis

Central (gonadotropin-dependent) precocious puberty, idiopathic

Clinical Reasoning

Breast development before age 8 in girls defines precocious puberty. The pubertal LH response to GnRH stimulation confirms central activation of the hypothalamic-pituitary-gonadal axis. The advanced bone age and accelerated growth velocity indicate significant estrogen exposure. Normal brain MRI excludes hypothalamic hamartoma or other CNS lesions, supporting idiopathic central precocious puberty, which is most common in girls.

Management

  1. GnRH agonist therapy: Leuprolide depot 7.5 mg IM monthly or 11.25 mg every 3 months to suppress the HPG axis
  2. Treatment goals: Slow pubertal progression, normalize growth velocity, preserve adult height potential, address psychosocial concerns
  3. Monitoring: Follow height velocity, Tanner staging, bone age, and LH/FSH levels every 6 months
  4. Psychological support: Age-appropriate counseling about body changes
  5. Treatment duration: Continue until average age of puberty (typically age 10-11), then discontinue to allow normal pubertal progression

Clinical Image

Image Description: Tanner staging diagram showing the five stages of female breast development used to assess pubertal progression.

Source: Wikimedia Commons URL: https://commons.wikimedia.org/wiki/File:Tanner_stages_female.svg License: CC BY-SA 4.0

All cases for this lecture as Markdown